A recent study in Nature Materials introduces an inhalable nanozyme treatment for viral pneumonia, showing promising results in reducing inflammation and viral load in various mouse models. The nanozyme, CeTA-K1tkP, demonstrates broad-spectrum effects and biocompatibility, offering a potential new approach to treating pneumonia and other inflammatory conditions.